All In Biotech

Drug Trial Radar · NCT07449741

Phase I Study of HXN6005 in Adult Healthy Participants

A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamics of HXN6005 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Apr 27, 2026

Primary completion

Mar 13, 2027

Study completion Mar 13, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamics of HXN6005 in Healthy Participants. Researchers will compare HXN6005 to a placebo (a look-alike substance that contains no drug). Participants will take a single dose of HXN6005 or placebo on Day 1, and visit the clinic for followup and tests per the protocol scheme.

Conditions

  • Healthy Volunteers (HV)

Interventions

  • HXN6005Drug

    participants will receive a single subcutaneous dose of HXN6005 at escalating dose levels in Cohort 1-4,

  • PlaceboDrug

    Participants will receive matching placebo across cohorts 1-4 of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse EventsTime frame: Up to Day 141

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Veritus Research

    Bayswater, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.